Quantity of eligible patients: CDEC discussed the uncertainty in the volume of people with reasonably critical to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be labeled as possessing mild or moderate disease may have a critical bleeding https://hemgenix95937.blogpixi.com/36020332/everything-about-hemgenix